Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: An open-label, long-term extension study

Hisashi Yamanaka, Yoshiya Tanaka, Tsutomu Takeuchi, Naonobu Sugiyama, Hirotoshi Yuasa, Shigeyuki Toyoizumi, Yosuke Morishima, Tomohiro Hirose, Samuel Zwillich

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Here, tofacitinib safety and efficacy data from a long-term extension study in Japanese patients are presented. Methods: Study A3921041 was a multi-centre, open-label, long-term extension study that included Japanese patients who had participated in a prior Phase 2 or Phase 3 study of tofacitinib as monotherapy or with background methotrexate. Patients received tofacitinib 5 mg twice daily (BID) or tofacitinib 10 mg BID. Dose adjustment of tofacitinib during treatment period, and concomitant usage of disease-modifying antirheumatic drugs including methotrexate after week 12 were permitted. Primary endpoints were adverse events, laboratory parameters and vital signs. Secondary efficacy endpoints included American College of Rheumatology (ACR)20/50/70 response rates, Disease Activity Score (DAS)28-4(erythrocyte sedimentation rate (ESR))

Original languageEnglish
JournalArthritis Research and Therapy
DOIs
Publication statusAccepted/In press - 2016 Jan 28

Fingerprint

Janus Kinases
Methotrexate
Rheumatoid Arthritis
Antirheumatic Agents
Vital Signs
Blood Sedimentation
tofacitinib
Safety
Therapeutics

Keywords

  • Japanese
  • Long-term extension
  • Rheumatoid arthritis
  • Tofacitinib

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis : An open-label, long-term extension study. / Yamanaka, Hisashi; Tanaka, Yoshiya; Takeuchi, Tsutomu; Sugiyama, Naonobu; Yuasa, Hirotoshi; Toyoizumi, Shigeyuki; Morishima, Yosuke; Hirose, Tomohiro; Zwillich, Samuel.

In: Arthritis Research and Therapy, 28.01.2016.

Research output: Contribution to journalArticle

Yamanaka, Hisashi ; Tanaka, Yoshiya ; Takeuchi, Tsutomu ; Sugiyama, Naonobu ; Yuasa, Hirotoshi ; Toyoizumi, Shigeyuki ; Morishima, Yosuke ; Hirose, Tomohiro ; Zwillich, Samuel. / Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis : An open-label, long-term extension study. In: Arthritis Research and Therapy. 2016.
@article{93129d6e5fb94871bd4076e2834a3be9,
title = "Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: An open-label, long-term extension study",
abstract = "Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Here, tofacitinib safety and efficacy data from a long-term extension study in Japanese patients are presented. Methods: Study A3921041 was a multi-centre, open-label, long-term extension study that included Japanese patients who had participated in a prior Phase 2 or Phase 3 study of tofacitinib as monotherapy or with background methotrexate. Patients received tofacitinib 5 mg twice daily (BID) or tofacitinib 10 mg BID. Dose adjustment of tofacitinib during treatment period, and concomitant usage of disease-modifying antirheumatic drugs including methotrexate after week 12 were permitted. Primary endpoints were adverse events, laboratory parameters and vital signs. Secondary efficacy endpoints included American College of Rheumatology (ACR)20/50/70 response rates, Disease Activity Score (DAS)28-4(erythrocyte sedimentation rate (ESR))",
keywords = "Japanese, Long-term extension, Rheumatoid arthritis, Tofacitinib",
author = "Hisashi Yamanaka and Yoshiya Tanaka and Tsutomu Takeuchi and Naonobu Sugiyama and Hirotoshi Yuasa and Shigeyuki Toyoizumi and Yosuke Morishima and Tomohiro Hirose and Samuel Zwillich",
year = "2016",
month = "1",
day = "28",
doi = "10.1186/s13075-016-0932-2",
language = "English",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis

T2 - An open-label, long-term extension study

AU - Yamanaka, Hisashi

AU - Tanaka, Yoshiya

AU - Takeuchi, Tsutomu

AU - Sugiyama, Naonobu

AU - Yuasa, Hirotoshi

AU - Toyoizumi, Shigeyuki

AU - Morishima, Yosuke

AU - Hirose, Tomohiro

AU - Zwillich, Samuel

PY - 2016/1/28

Y1 - 2016/1/28

N2 - Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Here, tofacitinib safety and efficacy data from a long-term extension study in Japanese patients are presented. Methods: Study A3921041 was a multi-centre, open-label, long-term extension study that included Japanese patients who had participated in a prior Phase 2 or Phase 3 study of tofacitinib as monotherapy or with background methotrexate. Patients received tofacitinib 5 mg twice daily (BID) or tofacitinib 10 mg BID. Dose adjustment of tofacitinib during treatment period, and concomitant usage of disease-modifying antirheumatic drugs including methotrexate after week 12 were permitted. Primary endpoints were adverse events, laboratory parameters and vital signs. Secondary efficacy endpoints included American College of Rheumatology (ACR)20/50/70 response rates, Disease Activity Score (DAS)28-4(erythrocyte sedimentation rate (ESR))

AB - Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Here, tofacitinib safety and efficacy data from a long-term extension study in Japanese patients are presented. Methods: Study A3921041 was a multi-centre, open-label, long-term extension study that included Japanese patients who had participated in a prior Phase 2 or Phase 3 study of tofacitinib as monotherapy or with background methotrexate. Patients received tofacitinib 5 mg twice daily (BID) or tofacitinib 10 mg BID. Dose adjustment of tofacitinib during treatment period, and concomitant usage of disease-modifying antirheumatic drugs including methotrexate after week 12 were permitted. Primary endpoints were adverse events, laboratory parameters and vital signs. Secondary efficacy endpoints included American College of Rheumatology (ACR)20/50/70 response rates, Disease Activity Score (DAS)28-4(erythrocyte sedimentation rate (ESR))

KW - Japanese

KW - Long-term extension

KW - Rheumatoid arthritis

KW - Tofacitinib

UR - http://www.scopus.com/inward/record.url?scp=84957818542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957818542&partnerID=8YFLogxK

U2 - 10.1186/s13075-016-0932-2

DO - 10.1186/s13075-016-0932-2

M3 - Article

C2 - 26818974

AN - SCOPUS:84957818542

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

ER -